BioSpace News Archive

Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announces that it is supporting Cancer Scout as Proteomics provider.

MiNA Therapeutics Limited, the pioneer in small activating RNA therapeutics, announces that it has significantly expanded its senior leadership team with four new appointments to support the Company’s next phase of growth.

Helsinn Group and Fosun Pharmaceutical A.G. announced the signing of exclusive license and distribution agreements effective from October 1st 2021 in the territory of Mainland China for Aloxi®, Akynzeo® and anamorelin.

Swedish biotech company Salipro Biotech AB announced that it has entered into a collaboration and licensing agreement with AbCellera for access to its proprietary Salipro® Platform, which stabilizes challenging G protein coupled receptor, ion channel, and transporter antigens.

Healthy full-term infants born during the COVID-19 pandemic had substantially shorter hospital stays than those born before the pandemic, with no change in hospital readmissions after discharge, according to a new study led by researchers at Children’s Hospital of Philadelphia, in collaboration with colleagues at the Yale School of Medicine, Nemours duPont, and Epic Systems Corporation.

Evofem Biosciences, Inc. announced that it has entered into a definitive agreement with Keystone Capital Partners providing for the issuance and sale of an aggregate of 10,000 shares of Series B Convertible Stock in a registered direct offering for a purchase price of $1,000.00 per share.

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, announced that Mark Smith, PhD, Chief Executive Officer, will present at the Jefferies Virtual Next Generation IBD Therapeutics Summit on Tuesday, October 19, 2021.

InflaRx N.V. announced today the completion of enrollment of the Phase III part of the Phase II/III vilobelimab study in severe COVID-19 patients.

Soligenix, Inc. announced today their poster abstract was selected as a “top abstract winner” and has been accepted for display and presentation at the 2021 National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit to be held virtually on October 18-19, 2021.

Spero Therapeutics, Inc. today announced the appointment of Kathleen Tregoning to its Board of Directors.